Skip to contentpdufa.bio

CLN-978 (CD19xCD3 T cell engager)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

CLN-978 (CD19xCD3 T cell engager) is a Cullinan Therapeutics, Inc. program in SLE, RA, Sjogren's disease. Its next catalyst is a Readout in Dec 2026.

CGEM catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: SLE, RA, Sjogren's disease. Sponsor: Cullinan Therapeutics, Inc. (CGEM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026CGEM

Specialist biotech funds holding CGEM, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
BVF Inc.5,750,683$88.3 millionfiled November 16, 2026
RTW Investments2,364,347$36.3 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is CLN-978 (CD19xCD3 T cell engager)'s next FDA decision or readout?

The next tracked catalyst for CLN-978 (CD19xCD3 T cell engager) is a Readout in Dec 2026.

What happened at CLN-978 (CD19xCD3 T cell engager)'s most recent FDA decision?

No FDA decision for CLN-978 (CD19xCD3 T cell engager) is in our archive yet.

What is CLN-978 (CD19xCD3 T cell engager) used for?

In our records CLN-978 (CD19xCD3 T cell engager) is under review or in development for SLE, RA, Sjogren's disease.

Who makes CLN-978 (CD19xCD3 T cell engager)?

Cullinan Therapeutics, Inc. (CGEM).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.